#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
# Clinical Summary Edible cannabis dosing represents a significant challenge in cannabinoid therapeutics due to highly variable bioavailability, hepatic first-pass metabolism, and individual differences in absorption that can result in 5-fold variations in plasma cannabinoid levels among patients receiving identical doses. Unlike inhaled cannabis, which produces rapid onset but shorter duration of effect, edibles undergo hepatic metabolism converting delta-9-tetrahydrocannabinol (THC) to the more potent metabolite 11-hydroxy-THC, leading to delayed onset (1-2 hours), prolonged duration (4-8 hours), and unpredictable clinical effects. Patient factors including fasting status, gastric pH, individual CYP3A4 and CYP2C9 enzyme activity, body composition, and previous cannabis exposure significantly influence edible pharmacokinetics, necessitating individualized titration rather than population-based dosing recommendations. Clinicians counseling patients on edible cannabis should recommend starting with low doses (2.5-5 mg THC), waiting at least two hours before assessing effects, and titrating slowly to minimize adverse events including anxiety, impaired cognition, and accidental overdose particularly in opioid-tolerant or cannabinoid-naive populations. The practical takeaway for clinicians is that edible dosing requires explicit patient education on delayed onset and the critical importance of dose titration to optimize therapeutic benefit while minimizing the risk of overconsumption-related adverse effects.
“Edible dosing remains one of the most individualized aspects of cannabis therapeutics, and it’s where we see the widest variation in patient response due to differences in metabolism, gut function, and prior exposure. The peer-reviewed literature supports a ‘start low and go slow’ approach, titrating upward over weeks rather than days, but we still lack standardized dosing guidelines across different patient populations, which is why this conversation really needs to happen between clinician and patient rather than relying on package labeling alone.”
💊 While consumer-focused edible dosing guides can offer practical reference points, clinicians should recognize that cannabis edible dosing remains highly individualized and poorly standardized across products due to variable cannabinoid concentrations, differences in fat solubility affecting absorption, and wide inter-individual variation in metabolism and sensitivity. The evidence base for specific therapeutic dosing in edibles is sparse compared to conventional pharmaceuticals, and many published recommendations derive from anecdotal experience rather than controlled trials. Relevant confounders include patient factors such as cannabis naivety, concurrent medications affecting CYP3A4 metabolism, gastrointestinal conditions altering absorption, and product variability even within regulated markets. Clinicians counseling patients on medical cannabis edibles should emphasize starting with low doses, titrating slowly over days to weeks, and discussing the delayed onset and prolonged effects compared to inhaled cannabis, while documenting the specific product THC/CBD
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
